Japan · Delayed Price · Currency is JPY J-Pharma Company Description
J-Pharma Co., Ltd. is engaged in the research and development of pharmaceutical drugs in Japan.
The company researches and develops drugs targeting solute carrier (SLC) transporters, with emphasis on the LAT1 amino acid transporter.
It is developing several compounds for various medical indications, including nanvuranlat (JPH203), a novel small-molecule compound identified as a selective inhibitor of LAT1 and provide treatment for biliary tract cancer, as well as for colorectal cancer; JPH034 is characterized as high brain penetrance and development for disorders of the central nervous system, including non-relapsing secondary progressive multiple sclerosis and glioma; and JPT-0008 for solid tumor, autoimmune diseases, and rare diseases.
It also conducting clinical trail for biliary tract cancer and JPH034. The company was founded in 2005 and is based in Minato, Japan.
| Country | Japan |
| Founded | 2005 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Masuhiro Yoshitake |
Contact Details
Address: 8th Floor, VORT Hamamatsucho II Minato, 105-0013 Japan | |
| Phone | 81 3 6432 4270 |
| Website | j-pharma.com |
Stock Details
| Ticker Symbol | 520A |
| Exchange | Tokyo Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | April - March |
| Reporting Currency | JPY |
| ISIN Number | JP3387030004 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Masuhiro Yoshitake | Chief Executive Officer |
| Yutaka Fujimoto | Chief Financial Officer |